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a coincidence?
Amit Sastry1, Michael Wayne1, Justin Steele1, Mazen Iskandar1, Songyang Yuan2 and Avram M Cooperman1*Abstract
Three sporadic, synchronous, and separate lesions in the ampulla of Vater and the head of the pancreas presented
in an 81-year-old male. One was symptomatic and two were incidental. One was detected preoperatively
(the ampullary lesion) and two by examination of the resected specimen (the neuroendocrine and pancreatic
carcinomas). The case is summarized and the literature and the issue of commonality are reviewed.
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Multiple primary neoplasms (MPNs) develop in 5 to
10% of the population [1-4]. Synchronous lesions are
identified within 2 to 6 months of the primary tumor
and metachronous lesions after 6 months [5]. MPNs
may be in the same organ (infrequent) or different organs
(much more frequent).
Three synchronous, sporadic, separate tumors involving
the head of the pancreas are very rare (<0.5%) [5,6],
and suggest a causal relation. In our case, two of the three
were malignant - an adenosquamous cancer of the am-
pulla of Vater, and an adenocarcinoma of the head of
the pancreas - while the third, a neuroendocrine tumor
(NET), had “benign” features. We summarize the case,
and review the literature and possible connections be-
tween lesions.Case presentation
An 81-year-old male presented with painless jaundice of
1 week duration, preceded by nausea, anorexia and 4.5
kg weight loss. There was a history of coronary artery
disease and type II diabetes mellitus. Abnormal labora-
tory tests included a bilirubin of 11.1 mg/ dl, an alkaline
phosphatase of 481 U/L, and an aspartate and alanine
transaminase ratio of 303/262 U/L. Magnetic resonance* Correspondence: avram.cooperman@gmail.com
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the pancreas. An endoscopy, endoscopic retrograde cho-
langiopancreatogram, and endoscopic sonogram revealed
a bulbous ampulla suggesting a submucosal mass, which
was confluent with a mass in the head of the pancreas. It
was 2.6 cm, solid and irregular, and obstructed a dilated
bile and pancreatic duct. The impression was a pancreatic
or ampullary malignancy. The surgical impression was a
pancreatic malignancy invading the ampulla and duode-
num and, if health risks permitted, surgery was advised. A
biliary stent was placed at endoscopy, the jaundice cleared,
and after medical and cardiac clearance the patient under-
went surgery. Absent of metastases, a single lesion was
palpated in the head of the pancreas near the ampulla.
A pylorus preserving pancreaticoduodenectomy was
performed in January 2013. The patient’s postoperative
course was uneventful. He was discharged on postoper-
ative day 9. Despite chemotherapy, hepatic metastases
were noted by June 2013 and had increased by August
2013. He died in November 2013, 10 months after
surgery.Pathology
The gross and histological images are shown in Figures 1,
2 and 3. The periampullary tumor (Figure 1) was a 3.5-cm,
poorly differentiated adenosquamous carcinoma with lym-
phovascular and perineural invasion with metastases in one
out of 7 lymph nodes (T3N1). The tumor cells expressed
p63 and ck5/6 but not chromogranin and synaptophysin.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Adenosquamous carcinoma of the ampulla of Vater.
(A) Gross image of tumor. (B) Solid nests with focal glandular
formation. Hematoxylin and eosin stain, 400×.
Figure 2 Adenocarcinoma of uncinate process. (A) Gross image
of tumor with periampullary tumor above it. (B) Tumor consists of
variable sized and shaped invasive tumor glands in the background
diffuse stoma fibrosis. Hematoxylin and eosin stain, 100×.
Figure 3 Neuroendocrine tumor of the anterior pancreas.
Tumor shows the characteristic trabecular pattern and monotonous
cells of endocrine neoplasm. Hematoxylin and eosin stain, 100×.
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identified 1 cm from the ampullary lesion. It was a pan-
creatic ductal adenocarcinoma, 3.1 cm in size and mod-
erately differentiated, with perineural and peripancreatic
fat invasion. There was no lymph node or lymphovascu-
lar invasion (T3N0).
The third lesion in the anterior pancreatic head (Figure 3)
was a 1.2-cm, well differentiated NET with cystic degen-
eration, but no lymphovascular or perineural invasion
(T1N0). The mitotic rate was <2 mitoses/50 HPF (High-
power-field), and the tumor cells were positive for chro-
mogranin and synaptophysin with a low proliferation
rate by Ki67 of 1%.
An additional finding throughout the resected specimen
was chronic pancreatitis and high grade pancreatic intra-
ductal neoplasia (PanIN 3).
A diagram depicting the location and relation of each
tumor in the head of the pancreas is provided in Figure 4.
Discussion
MPN are not common, with an incidence of 5 to 10%
[1-4,6]. The prevalence of MPNs is increasing because of
Figure 4 The relationship of the three tumors in the head
of the pancreas. A, the adenosquamous ampullary cancer;
B, the adenocarcinoma of the head of the pancreas; C, the
neuroendocrine tumor.
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use of body imaging, longer survival of many cancer pa-
tients, lifestyle choices (smoking and alcohol), genetics,
environment, nutrition and immunology [7]. MPNs are
synchronous or metachronous. The definitions are arbi-
trary, implying detection within 2 or 6 months (synchron-
ous) or after 6 months (metachronous) from the primary
tumor [8]. A 44-month mean interval from treatment of
the primary tumor until detection of metachronous tu-
mors in one registry suggests that the longer the survival
after the primary tumor, the greater the chance for meta-
chronous lesions [9]. MPNs infrequently develop in the
same organ. When MPNs develop after exposure to the
same risk factors in different organs, they are designated
as “field cancerization” (for example, head and neck, and
breast-ovary and urogenital cancers [2,10]). Patients who
develop MPN in unrelated organs are “cancer prone”. De-
differentiation of cells from exocrine to ductal epithelial
cells, and the loss of alleles 3p and 10q on chromosome
10 are present in 40 to 50% of pancreatic serous cysta-
denomas and some pancreatic adenocarcinomas [11].
This may be a shared pathway for the development of
either lesion [12-15]. Chronic inflammation with high-
grade PanIN lesions which were pervasive in the resected
specimen are premalignant and are associated with a
higher risk for pancreatic adenocarcinoma [16]. Some
“unrelated” tumors are clonally related [17]. Unique to
our patient are three separate, synchronous pancreatic
epithelial lesions simultaneously detected. This is very
rare (prevalence of <0.5%) [3]. A third of synchronous
MPNs detected simultaneously occur in related organs
(breast-breast, breast-ovary, ovary-endometrium, pancreas-
biliary tree) [18,19].
Multiple reported synchronous pancreatic lesions in-
clude combinations of adenocarcinoma, NETs, and cystic
lesions. Usually two lesions are identified. Synchronouspancreatic adenocarcinomas and intraductal papillary
mucinous tumors (IPMNs) have been reported (most
are side-branch lesions) to coexist in 9% of cases [20].
One publication reported multi-centric pancreatic adeno-
carcinomas and a side branch IPMN. The patient initially
presented with an incidental side-branch IPMN, un-
changed for 6 years. A pancreatic duct irregularity (a 1.2-
cm cancer) was noted and the patient underwent a distal
pancreatic resection for a small carcinoma. Intraoperative
cytology after lavage of the remaining pancreatic duct
revealed malignant cells. The patient underwent total
pancreatectomy and three other adenocarcinomas were
found: two were in situ and the third was a 3-mm inva-
sive lesion. Despite the small size of the invasive lesions,
and normal markers, one metastatic node was present
[21]. Many MPNs share exposure to the same risk or
genetic factors [2,10]. In the pancreas, centroacinar and
duct cells differ in cells of origin but allele losses on
chromosome 10q are present in 50% of serous cyst ad-
enomas as well as some adenocarcinomas [11]. The
pathway involves mutations of the phosphatase and tensin
homolog gene, a tumor suppressor gene [15]. Adenocar-
cinoma of the pancreas may also coexist with gallbladder
and/or bile duct cancer [22,23]. When two synchronous
lesions are detected the symptomatic lesion is primary,
and the other lesion is incidental. Exocrine and endocrine
epithelial cells have similar morphologic and embryologic
origins and endocrine and epithelial tumors coexist in
1.3% of cases [12]. Immunostaining confirms that exocrine
cells do differentiate into ductal epithelial tumor cells
[12-14]. In our case, chronic pancreatitis with high-grade
PanIN 3 was found throughout the resected specimen. By
itself, chronic pancreatitis and chronic inflammation leads
to pancreatic neoplasia [16]. Although multiple etiologies
may coexist in patients with MPN, causality has been diffi-
cult to prove.
Ampullary cancer accounts for 1% of all gastrointes-
tinal malignancies, 6% of all periampullary cancers, and
are one-tenth as frequent as pancreatic cancer [24].
Ampullary adenosquamous cancers are very rare (perhaps
10 cases have been reported), with a dismal prognosis
[25]. Treatment is usually operative, either a pancreatico-
duodenectomy or ampullectomy. Survival is usually less
than 6 months, although two reported patients survived at
19 and 46 months [26]. Our patient lived 10 months after
surgery, although metastases were evident at 5 months.
The prognosis for ampullary adenosquamous cancer is
worse than for adenocarcinoma of the pancreas. Some
suggest that, if the diagnosis is made before treatment,
chemoradiation be the initial treatment [27].
The second lesion, a 3.1-cm adenocarcinoma of the
pancreas was an incidental lesion, not identified by
endoscopic sonogram or magnetic resonance imaging.
The dismal prognosis of pancreatic adenocarcinoma is
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detected by serial screening the prognosis and cure
rates are poor [28].
The third lesion was a small (1.2 cm) pancreatic NET
with cystic degeneration. As body imaging has become
common, small incidental NETs are frequently discovered
[28]. Although considered low-grade malignancies, they
are slow growing, and generally "well behaved". By itself, a
1.2-cm nonfunctional lesion would be observed. Only 79
malignant pancreatic NETs of the pancreas have been re-
ported since 1973, of which more than three-quarters
were metastatic with a 5-year survival of 37.5% [29].
Conclusions
An 81-year-old male who presented with jaundice was
found to have an ampullary cancer and an incidental
pancreatic adenocarcinoma and a neuroendocrine cystic
lesion. After stenting of the bile duct and medical clear-
ance, a pancreaticoduodenal resection was performed. The
postoperative course was uneventful. The pathology report
noted an obstructive ampullary adenosquamous cancer - a
rare, highly malignant and dismal tumor. Two synchron-
ous lesions, a 3-cm adenocarcinoma of the pancreas, and a
1.2-cm NET were identified as separate lesions in the
resected specimen. Metastases were evident at 5 months
and the patient died at 10 months.
Consent
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